Mochida Pharmaceutical (4534)

Currency in JPY
3,160.0
-15.0(-0.47%)
Closed·
Advertisement
4534 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3,135.03,170.0
52 wk Range
2,929.03,965.0
Key Statistics
Bid/Ask
3,150.00 / 3,200.00
Prev. Close
3,175
Open
3,140
Day's Range
3,135-3,170
52 wk Range
2,929-3,965
Volume
56.7K
Average Volume (3m)
57.05K
1-Year Change
-2.0155%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4534 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Earnings

Latest Release
03/08/2026
EPS / Forecast
89.77 / --
Revenue / Forecast
31.72B / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 259.23%
Dividend Yield
2.61%
Industry Median 2.48%
Annualised payout
82.50
Paid unevenly
5-Years Growth
-2.33%
Growth Streak

Compare 4534 to Peers and Sector

Metrics to compare
4534
Peers
Sector
Relationship
P/E Ratio
12.1x14.1x−0.3x
PEG Ratio
0.230.130.00
Price/Book
0.8x0.8x2.6x
Price / LTM Sales
0.9x1.0x3.0x
Upside (Analyst Target)
-19.4%54.6%
Fair Value Upside
Unlock15.5%8.6%Unlock

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcerative lung disease; Uris, for gout and hyperuricemia; and Clorox, for ulcerative colitis; Epadel for hyperlipidemia and obstructive arteriosclerosis; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker antihypertensive drug; Heparin Na anticoagulants; and Onboard, ulcerative colitis and Crohn's disease treatment agents. In addition, it develops medical devices, including dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for adhesion prevention material. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products, as well as academic research and marketing. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Shinjuku, Japan.

Employees
1479
Market
Japan

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.83M10.85%12.15B
Other Institutional Investors
13.52M38.33%42.91B
Public Companies & Retail Investors
17.92M50.82%56.90B
Total
35.26M100.00%111.96B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Mochida Memorial Foundation for Medical and Pharmaceutical Research16.13%5,688,67418,061,540
Princess Takamatsu Cancer Research Fund4.77%1,683,0005,343,525

FAQ

What Is the Mochida Pharmaceutical (Tokyo: 4534) Share Price Today?

The Mochida Pharmaceutical stock price today is 3,160.0 JPY.

What Stock Exchange Does Mochida Pharmaceutical (4534) Trade On?

Mochida Pharmaceutical is listed and trades on the Tokyo Stock Exchange.

What Is the Ticker (Stock Symbol) for Mochida Pharmaceutical?

The stock symbol (also called a 'ticker') for Mochida Pharmaceutical is "4534."

Does Mochida Pharmaceutical Pay Dividends? What’s The Current 4534 Dividend Yield?

Yes, 4534 Pays Dividends to its Shareholders. The current Mochida Pharmaceutical dividend yield is 2.6%.

What Is the Current Mochida Pharmaceutical Market Capitalisation?

As of today, Mochida Pharmaceutical (Tokyo: 4534) market cap is 111.43B JPY.

What Is Mochida Pharmaceutical's (4534) Earnings Per Share (TTM)?

The Mochida Pharmaceutical EPS is currently 259.2 (Trailing Twelve Months).

When Is the Next Mochida Pharmaceutical Earnings Date?

Mochida Pharmaceutical's next earnings report will be released on 30/10/2026.

Is 4534 a Buy or Sell From a Technical Analyst Perspective?

Based on today's Mochida Pharmaceutical moving averages and other technical indicators, the daily buy/sell signal for 4534 stock is Strong Sell.

How Many Times Has Mochida Pharmaceutical Stock Split?

Mochida Pharmaceutical has split 4 times. (See the 4534 stock split history page for full effective split date and price information.)

How Many Employees Does Mochida Pharmaceutical Have?

Mochida Pharmaceutical has 1479 employees, based on their latest Companies House report.

What is the current trading status of Mochida Pharmaceutical (Tokyo: 4534)?

As of 12/09/2026, Mochida Pharmaceutical (4534) is trading at a share price of 3,160.0 JPY, with a previous close of 3,175.0 JPY. The stock has fluctuated within a day range of 3,135.0 JPY to 3,170.0 JPY, while its 52-week range spans from 2,929.0 JPY to 3,965.0 JPY.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.